Introduction
Biosimilar Aggregation Analysis sits at the center of every biosimilar comparability program, because protein aggregates — whether a few nanometers or several microns in size — can compromise product safety, reduce shelf life, and raise immunogenicity concerns. Demonstrating that a proposed biosimilar matches its reference product’s aggregation profile is not optional; it is a core requirement under FDA and EMA biosimilarity guidance. At ResolveMass Laboratories Inc., a USFDA-registered Canadian contract research organization, we built a dedicated Biosimilar Aggregation and Particle Analysis service around three complementary techniques — SEC-MALS, DLS, and MFI — so that no part of the aggregate size distribution goes unmeasured. This article explains what each method does, when to use it, and how these techniques fit together inside a regulatory-ready analytical package.
Summary:
- Biosimilar Aggregation Analysis evaluates protein aggregates across the full size range — from soluble dimers to visible particles — because aggregation can affect efficacy and trigger unwanted immune responses.
- SEC-MALS measures soluble aggregates (dimers, oligomers, fragments) and reports absolute molecular weight, independent of column calibration.
- DLS (Dynamic Light Scattering) screens for aggregation tendency and size distribution in solution, often used early in formulation development.
- MFI (Micro-Flow Imaging) images and counts subvisible particles in the 1–100 micron range, capturing morphology that other methods miss.
- Regulators (FDA, EMA, ICH Q6B, USP <787>/<788>) expect a multi-method, orthogonal approach — no single technique covers the entire aggregate size spectrum.
- ResolveMass Laboratories Inc. combines SEC-MALS, DLS, and MFI in GLP-aligned workflows to support biosimilar comparability, formulation stability, and regulatory submission packages.
1: Why Does Aggregation Matter in Biosimilar Development?
Protein aggregation matters because aggregates are one of the most common causes of immunogenicity and loss of potency in biologic drugs, and regulators treat aggregate content as a critical quality attribute (CQA) that must be matched between a biosimilar and its reference product. A single misfolded or aggregated antibody species can act as a multivalent antigen, increasing the risk that a patient’s immune system raises anti-drug antibodies (ADAs). Beyond safety, aggregation can also reduce the effective dose of active monomer reaching the patient, undermining clinical efficacy.
Because aggregates form across a continuum — from soluble dimers measured in nanometers to visible particles measured in millimeters — no single analytical method can characterize the entire range. This is why regulatory guidance, including ICH Q6B and USP General Chapters <787> and <788>, calls for an orthogonal, multi-technique approach.
2: What Is SEC-MALS and How Does It Detect Soluble Aggregates?
SEC-MALS (Size-Exclusion Chromatography coupled with Multi-Angle Light Scattering) separates protein species by size and then measures their absolute molecular weight directly, without relying on column calibration against reference standards. This makes it the workhorse technique for quantifying soluble aggregates such as dimers, trimers, and higher-order oligomers, as well as detecting fragmentation.
Key advantages of SEC-MALS for biosimilar aggregation analysis:
- Provides absolute molecular weight, not an estimate based on a standard curve
- Resolves and quantifies individual aggregate species (dimer, trimer, HMW species)
- Detects fragments and clips that simple UV-based SEC can miss
- Generates the chromatographic aggregate profile regulators expect in comparability submissions
Where SEC-MALS Fits in a Comparability Study
SEC-MALS is typically the first-line method used to compare the percent monomer, percent high-molecular-weight (HMW) species, and percent low-molecular-weight (LMW) species between a biosimilar candidate and its reference product. Because the output is a quantitative chromatographic fingerprint, it integrates directly into batch-release specifications and stability-indicating methods.
3: What Is DLS and When Should It Be Used?
DLS (Dynamic Light Scattering) measures the rate at which particles diffuse in solution due to Brownian motion, converting that diffusion rate into a hydrodynamic size distribution within minutes and using only microliters of sample. DLS is most valuable as a rapid screening tool during early formulation development, where dozens of buffer, pH, and excipient conditions need to be compared quickly to identify aggregation-prone formulations before committing material to lower-throughput methods.
Typical DLS applications include:
- Early-stage formulation and excipient screening
- Monitoring aggregation onset under stress conditions (heat, freeze-thaw, agitation)
- Polydispersity index (PdI) assessment as an early warning sign of instability
- Real-time, non-destructive measurement that preserves sample for further testing
DLS is sensitive but not highly resolving — it reports an intensity-weighted average size distribution rather than discrete, quantified species. For that reason, DLS results are best interpreted alongside SEC-MALS data rather than as a standalone comparability measurement.
4: What Is MFI and Why Is It Needed for Subvisible Particles?
MFI (Micro-Flow Imaging) flows a liquid sample past a high-resolution camera that captures digital images of individual particles, allowing both the count and the morphology of subvisible particles, generally in the 1–100 micron range, to be recorded. Unlike light obscuration, which only reports particle count and size, MFI captures actual particle images, making it possible to distinguish protein aggregates from silicone oil droplets, air bubbles, glass delamination flakes, or other extrinsic contaminants.
Why MFI matters for biosimilar particle analysis:
| Capability | MFI | Light Obscuration |
|---|---|---|
| Particle imaging/morphology | Yes | No |
| Differentiates protein vs. non-protein particles | Yes | Limited |
| Compliant with USP <787>/<788> | Yes | Yes |
| Useful for root-cause investigations | Yes | Limited |
MFI is particularly important for prefilled syringes, autoinjectors, and other combination products, where silicone oil and device-related particulates are common confounders that simple counting methods cannot distinguish from genuine protein aggregates.
5: SEC-MALS vs. DLS vs. MFI: How Do the Methods Compare?
Each technique covers a different slice of the aggregate size spectrum, and a complete Biosimilar Aggregation Analysis package uses all three together rather than relying on any single method.
| Method | Size Range Covered | Primary Output | Best Used For |
|---|---|---|---|
| SEC-MALS | ~1–100 nm (soluble aggregates) | Absolute MW, quantified aggregate species | Comparability submissions, batch release |
| DLS | ~1 nm–1 µm | Hydrodynamic size distribution, PdI | Formulation screening, stress studies |
| MFI | ~1–100 µm (subvisible particles) | Particle count, size, and images | Subvisible particle characterization, root-cause analysis |
Used together, these methods build a continuous picture of aggregation from the smallest soluble dimer through to subvisible particulates, which is exactly the “totality of evidence” regulators expect to see in a biosimilar comparability package.
6: How Does ResolveMass Laboratories Approach Biosimilar Aggregation Analysis?
ResolveMass Laboratories Inc. approaches Biosimilar Aggregation Analysis as an integrated, orthogonal testing package rather than a single isolated assay, combining SEC-MALS, DLS, and MFI data into one comparability report aligned with FDA, EMA, and ICH expectations. As a USFDA-registered laboratory, our team works under GLP-aligned, validated workflows, with experienced scientists who routinely support IND-enabling, biosimilar comparability, and post-approval stability programs for pharmaceutical and biotech sponsors across North America and beyond.
Our process typically includes:
- Method development and qualification specific to the molecule and formulation
- SEC-MALS analysis for absolute molecular weight and soluble aggregate quantification
- DLS-based formulation and forced-degradation screening
- MFI imaging for subvisible particle counting and characterization
- Side-by-side comparison against the reference biologic, with a regulatory-ready report
This orthogonal strategy reduces the risk of submission delays caused by gaps in aggregate characterization, and it gives formulation scientists the data needed to make informed decisions earlier in development, rather than discovering stability issues late in the program.
7: Common Questions About Biosimilar Aggregation Analysis
Does aggregation always indicate a quality problem? Not necessarily — a small, well-characterized, and consistent level of aggregation can fall within an acceptable specification range, as long as it matches the reference product’s profile and remains stable over the product’s shelf life.
Can one method alone satisfy regulatory requirements? No single method covers the full aggregate size range, so regulatory guidance expects an orthogonal combination of techniques such as SEC-MALS, DLS, and MFI, supplemented where needed by light obscuration or analytical ultracentrifugation.
How early in development should aggregation analysis begin? Aggregation screening should begin during early formulation development using fast methods like DLS, then expand to SEC-MALS and MFI as the program moves toward comparability and stability studies.
Conclusion:
Biosimilar Aggregation Analysis is not a single test but a coordinated strategy spanning soluble aggregates, hydrodynamic size distributions, and subvisible particles. SEC-MALS quantifies soluble aggregate species with absolute molecular weight precision, DLS offers fast, low-volume screening during formulation development, and MFI fills the critical subvisible particle gap with image-based particle characterization. Together, these three orthogonal methods give biosimilar developers the complete aggregate profile that regulators require for comparability and stability submissions. ResolveMass Laboratories Inc. brings these techniques together under one GLP-aligned analytical program, helping sponsors generate the robust, regulatory-ready aggregation data needed to move biosimilar programs forward with confidence.
Frequently Asked Questions:
Protein aggregates can alter the biological activity of a therapeutic protein and potentially trigger unwanted immune responses in patients. Excessive aggregation may reduce product potency, affect shelf life, and create comparability challenges during regulatory review. Monitoring aggregate formation helps manufacturers maintain product quality and ensure biosimilarity to the reference product.
Size Exclusion Chromatography coupled with Multi-Angle Light Scattering (SEC-MALS) separates proteins based on size and measures their absolute molecular weight. This technique enables accurate quantification of monomers, dimers, oligomers, and high molecular weight species. SEC-MALS is widely used in biosimilar characterization because it provides reliable aggregate profiling and supports comparability assessments.
Dynamic Light Scattering (DLS) measures particle size distribution by analyzing fluctuations in scattered light caused by Brownian motion. It is particularly useful for detecting early-stage aggregation and monitoring formulation stability. DLS requires minimal sample preparation and provides rapid insights into protein size and sample homogeneity during development and stability studies.
Microflow Imaging (MFI) is an image-based particle analysis technique used to detect and characterize subvisible particles in biologic formulations. Unlike traditional particle counting methods, MFI captures images of individual particles, enabling assessment of size, shape, and morphology. This helps distinguish protein aggregates from silicone oil droplets, glass particles, and other contaminants.
No single analytical technique can fully characterize all forms of protein aggregates and particles. SEC-MALS, DLS, and MFI each provide unique information about aggregate size, molecular weight, and particle morphology. Using orthogonal methods improves data reliability, strengthens scientific conclusions, and aligns with regulatory expectations for comprehensive biosimilar characterization.
Together, these techniques can detect a wide range of aggregate species, including soluble oligomers, high molecular weight aggregates, submicron particles, and subvisible particles. SEC-MALS is ideal for soluble aggregate quantification, DLS evaluates particle size distribution, and MFI characterizes larger particles and their physical appearance. The combined approach provides complete aggregate coverage.
Reference
- Zhang L, Yu L, Xu Y, Qin P, Shen P, Liu K, Fei M, Wang H, Cao Y, Lu L, Gao W. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes. Analytical & Bioanalytical Chemistry. 2023 Jul 11;415(17):3341.https://openurl.ebsco.com/contentitem/gcd:164492169?sid=ebsco:plink:crawler-gcd&id=ebsco:gcd:164492169&crl=c&jrnl=16182642
- Nirmal DN, Kulkarni S. IgG Monoclonal Antibodies: Analytical Perspectives. Applied Research. 2025 Dec;4(6):e70055.https://onlinelibrary.wiley.com/doi/abs/10.1002/appl.70055
- Cheng Y, Saggu M, Thomas JC. Analysis of aggregates and particles. InProtein Instability at Interfaces During Drug Product Development: Fundamental Understanding, Evaluation, and Mitigation 2021 Feb 13 (pp. 199-226). Cham: Springer International Publishing.https://link.springer.com/chapter/10.1007/978-3-030-57177-1_8
- Neves Sao Pedro M. Miniaturization of Process Analytical Technology: from Concept to Reality.https://repository.tudelft.nl/file/File_914973de-92c0-44e2-a533-0a069868718d
About the Author
